Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Chronic cholestasis often results in premature death from liver failure with fibrosis; however, the molecular mechanisms contributing to biliary cirrhosis are not demonstrated. In this article, we show that the death signal mediated by TNF-related apoptosis-inducing ligand (TRAIL) receptor 2/death receptor 5 (DR5) may be a key regulator of cholestatic liver injury. Agonistic anti-DR5 monoclonal antibody treatment triggered cholangiocyte apoptosis, and subsequently induced cholangitis and cholestatic liver injury in a mouse strain-specific manner. TRAIL- or DR5-deficient mice were relatively resistant to common bile duct ligation-induced cholestasis, and common bile duct ligation augmented DR5 expression on cholangiocytes, sensitizing mice to DR5-mediated cholangitis. Notably, anti-DR5 monoclonal antibody-induced cholangitis exhibited the typical histological appearance, reminiscent of human primary sclerosing cholangitis. Human cholangiocytes constitutively expressed DR5, and TRAIL expression and apoptosis were significantly elevated in cholangiocytes of human primary sclerosing cholangitis and primary biliary cirrhosis patients. Thus, TRAIL/DR5-mediated apoptosis may substantially contribute to chronic cholestatic disease, particularly primary sclerosing cholangitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360 · cited 4×
“Recombinant TRAIL and anti-DR4 or DR5 monoclonal antibodies (mAbs) were reported to be substantially tumoricidal in mice without apparent toxicity (10–14), and have now started to be applied in cancer therapy (3, 9, 15, 16).”
BackgroundInfluentialBid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
Yin, X.-M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K. A., & Korsmeyer, S. J. (1999) · Nature · doi:10.1038/23730 · Cited by 1,004 · cited 1×
“The mitochondrial pathway of apoptosis appeared to play a limited role in anti-DR5 mAb-induced cholestatic liver injury, because disease onset was only partly delayed in B6 Bid / mice that are resistant to Fas-induced hepatocellular apoptosis (26) [supporting information (SI) Fig.”
BackgroundJo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 775 · cited 2×
“TRAIL has been also demonstrated as a critical molecule in extrinsic tumor suppression by the immune system (3, 7, 8), and thus TRAIL is of great interest to clinical oncologists (3, 9).”
BackgroundResultSelf-citationDifferential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Research works printed but not linked: 2
- 10.1111/j.1572-0241.2002.05585.x · doi:10.1111/j.1572-0241.2002.05585.x · Paper page
- 10.1053/jhep.2001.25173a · doi:10.1053/jhep.2001.25173a
Cited by
Items 101–147 of 147
Martin, B. P., Frew, A. J., Bots, M. L., Fox, S. B., Long, F., Takeda, K., Yagita∥, H., Atadja, P. W., Smyth, M. J., & Johnstone, R. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25594 · Cited by 14
“, hepatocytes and keratinocytes) by certain rTRAIL formulations and anti-TRAIL-R mAb was reported in vitro, and two recent studies have shown that the TRAIL/DR5 pathway may contribute to hepato- and/or bile duct toxicity in mice either treated with antimouse DR5 mAbs or intervened by bile duct ligation.(25,26)”
BackgroundResultSelf-citationYang, F., Gaudio, E., Onori, P., Wise, C., Alpini, G. D., & Glaser, S. S. (2010) · Journal of Cell Death · doi:10.4137/jcd.s2785 · Cited by 16
Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease
Bernard, J. K., Marakovits, C. N., Smith, L., & Francis, H. (2023) · Seminars in Liver Disease · doi:10.1055/a-2104-9034 · Cited by 15
Zebrafish ppp1r21 mutant as a model for the study of primary biliary cholangitis
Wu, C., Zhang, W., Luo, Y., Cheng, C., Wang, X., Jiang, Y., Li, S., Luo, L., & Yang, Y. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.05.013 · Cited by 12
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors
Lee, S., Yagita∥, H., Sayers, T. J., & Celis, E. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0834-0 · Cited by 12
“[26] have demonstrated an interesting observation that a-DR5 mAb injection induced cholangitis and hepatic injury by apoptosis of cholangiocytes in B6 mice, but not in Balb/c mice.”
Self-citationMalhi, H., & Gores, G. J. (2011) · Wiley eBooks · doi:10.1002/9781119950509.ch8 · Cited by 12
Immunobiology of bile and cholangiocytes
Yang, L., Leung, P. S. C., Zhang, W., Zhang, S., Liu, Z., Kurth, M. J., Patterson, A. D., Gershwin, M. E., & Song, J. (2025) · Journal of Autoimmunity · doi:10.1016/j.jaut.2025.103376 · Cited by 13
Shivange, G., Mondal, T., Lyerly, E., Bhatnagar, S., Landen, C. N., Reddy, S., Kim, J., Doan, B., Riddle, P., & Tushir‐Singh, J. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109953 · Cited by 8
“The p values are determined by a two-tailed paired Wilcoxon MannWhitney test (Takeda et al., 2008).”
MethodMalhi, H., & Gores, G. J. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch7 · Cited by 9
Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy
Wamba, B. E. N., Mondal, T., Freenor, F., V, Shaheed, M., Pang, O., Bedinger, D., Legembre, P., Devel, L., Bhatnagar, S., Leiserowitz, G. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60990-0 · Cited by 8
“Both cells very highly consistently in forming tumors (19 out of 20) within ~2 – 3 weeks as published 91 .”
Juran, B. D., McCauley, B. M., Atkinson, E. J., Schlicht, E. M., Bianchi, J. K., Vollenweider, J. M., Ye, H., LaRusso, N. F., Gores, G. J., Sun, Z., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000496 · Cited by 10
“…a death receptor ligand that induces apoptosis of cells expressing its cognate receptors that has been previously studied in the context of PSC. [39] A further 437 CpGs mapping to 273 additional genes achieved SGsig and included 5 MHC class II genes (HLA-DQB1, -DQB2, -DRA, -DRB1, and -DRB5) as…”
BackgroundMizuguchi, Y., Specht, S. M., Isse, K., Lunz, J. G., & Demetris, A. J. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_4 · Cited by 7
Death Receptor 5 and Neuroproliferation
Niu, Y., Li, Y., Zang, J., Huang, H., Deng, J., Cui, Z., 于东明, & Deng, J. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9757-3 · Cited by 12
“In human TRAIL-R1 and TRAIL-R2 are respectively the products of the TNFRSF10A and TNFRSF10B genes.”
BackgroundShimoda, S., & Tanaka, A. (2015) · Hepatology Research · doi:10.1111/hepr.12615 · Cited by 10
Cell Death in Drug-Induced Liver Injury
Dara, L., & Kaplowitz, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-53774-0_1 · Cited by 9
An Integrated Pathogenetic Model of Primary Biliary Cholangitis
Kouroumalis, E., Tsomidis, I., & Voumvouraki, A. (2025) · Livers · doi:10.3390/livers5020015 · Cited by 7
“Increased deoxyribonucleic acid (DNA) fragmentation and high levels of perforin, granzyme B, and TNF-related apoptosis-inducing ligand (TRAIL) have been shown in BECs from PBC cases [126–128].”
Frese, S., Schüller, A., Frese‐Schaper, M., Gugger, M., & Schmid, R. A. (2009) · PubMed · Cited by 6
Self-citationFrom Biochemical Principles of Apoptosis Induction by TRAIL to Application in Tumour Therapy
Cordier, S. M., Papenfuss, K., & Walczak, H. (2009) · Results and problems in cell differentiation · doi:10.1007/400_2008_27 · Cited by 6
Kawahara, T., Toso, C., Yamaguchi, K., Cader, S., Douglas, D. N., Nourbakhsh, M., Lewis, J. T., Churchill, T. A., Yagita∥, H., & Kneteman, N. M. (2013) · Liver International · doi:10.1111/liv.12275 · Cited by 5
“In addition, a mouse model showed that anti-DR5 mAb can cause cholangitis by inducing apoptosis of cholangiocytes (27).”
BackgroundMethodSelf-citationInvernizzi, P., Leung, P. S. C., Ma, X., & Gershwin, M. E. (2013) · Springer eBooks · doi:10.1007/978-3-319-02096-9_18 · Cited by 5
Natural killer cells in autoimmunity: clues or tools?
Folci, M. (2014) · Inflammation and Cell Signaling · doi:10.14800/ics.51 · Cited by 4
A Mouse Model of Autoimmune Cholangitis via Syngeneic Bile Duct Protein Immunization
Ma, W.-T., Liu, Q.-Z., Yang, J.-B., Yang, Y., Zhao, Z.-B., Ma, H.-D., Gershwin, M. E., & Lian, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-15661-6 · Cited by 4
Lian, Z., & Li, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_2 · Cited by 4
Primary Biliary Cholangitis Pathogenesis: A Pathophysiology-Based Narrative Review
Papachristou, K., Angelara, M., Manganas, K., & Ανδρουτσάκος, Θ. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031388 · Cited by 4
“…in immune dysregulation, accumulating evidence indicates that BECs in PBC patients show increased susceptibility to apoptosis compared with those in other cholestatic liver diseases as well as higher levels of Fas, FasL, perforin, granzyme B, and TNF-related apoptosis-inducing ligands [30,93,94].”
Interplay of autophagy, apoptosis, and senescence in primary biliary cholangitis
Kouroumalis, E., Tsomidis, I., & Voumvouraki, A. (2023) · Exploration of Digestive Diseases · doi:10.37349/edd.2023.00028 · Cited by 3
Zhang, Y., Chen, R., Yang, X., Qian, L., Shen, B., & Shuai, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1684064 · Cited by 3
Zen, Y., Hübscher, S. G., & Nakanuma, Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00009-0 · Cited by 3
Self-citationKimotsuki, T., Tanaka, K., Sugiura, T., Koyama, K., Nakamura, T., Kamimura, Y., Takasaki, W., & Manabe, S. (2010) · Journal of Toxicologic Pathology · doi:10.1293/tox.23.11 · Cited by 2
Programmed cell death and liver diseases
Онищенко, Н. А., Гоникова, З. З., Nikolskaya, A. O., Кирсанова, Л. А., & Sevastianov, V. I. (2022) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2022-1-72-88 · Cited by 3
Fukumoto, M., Soyama, A., Miyamoto, D., Hara, T., Matsushima, H., Imamura, H., Yamashita, M., Adachi, T., Kanetaka, K., & Eguchi, S. (2025) · Regenerative Therapy · doi:10.1016/j.reth.2025.04.015 · Cited by 2
“Moreover, CLiP may express DR5 similarly to cholangiocytes [21], making them more prone to innate immune attack.”
The Role of Cholangiocyte Cell Death in the Development of Biliary Diseases
O’Brien, A., Hall, C. M., Ehrlich, L., Zhou, T., Meng, F., Alpini, G. D., & Glaser, S. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-58106-4_2 · Cited by 1
Zhang, Y., Zhang, X., Chen, R., Jiao, Z., Shen, B. Q., & Shuai, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-2997966/v1 · Cited by 1
RBP4 functions as an antagonistic ligand of orphan DR6Preprint
Kim, T., Lee, W., Nguyen, T. N. C., Jang, J., Kim, K., Kim, M., Seo, D., Lee, Y.-S., & Lee, Y.-I. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.21.619555 · Cited by 1
Hermosillo‐Sandoval, J. M., Román-Pintos, L. M., Rodríguez-Carrizález, A. D., Cardona-Muñóz, E. G., Pacheco-Moisés, F. P., Ortíz, G. G., & Miranda‐Díaz, A. G. (2013) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2013.68a2008
“BDI represents one of the most complex and serious surgical complications that increases risk of death in patients [20].”
BackgroundStrategies in secondary biliary fibrosis
Hermosillo‐Sandoval, J. M., Rodríguez-Carrizález, A. D., & Miranda‐Díaz, A. G. (2013) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2013.68a2002
“BDI is a serious surgical complication that can have devastating effects, including the risk of premature death [13].”
BackgroundJohnson, M. (2012) · Materials and Methods · doi:10.13070/mm.fr.2.113
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014)
Natural Killer Cells in Autoimmunity
Chimenti, M. S., Conigliaro, P., Fonti, G. L., & Perricone, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814307-0.00007-4 · Cited by 1
Primary Sclerosing Cholangitis
Eaton, J. E., Talwalkar, J. A., & Lindor, K. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00063-0
PSC-Associated Cholangiocarcinoma: Diagnostic and Therapeutic Considerations
Cagnin, S., Tabibian, J. H., & Fabris, L. (2021) · Springer eBooks · doi:10.1007/978-3-030-70936-5_10
Johnson, M. (2012) · 实验材料和方法 · doi:10.13070/mm.cn.2.113
Li, Z., Gong, Y., Ye, L., & Liu, W. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000923 · Cited by 1
“[114] In addition, activating NK cells have been demonstrated to trigger TRAIL expression on H-NK cells, suggesting a potential mechanism for NK cell-induced collapse of cholangiocytes.”
Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis
Jawazneh, A. A., Liebold, I., Leyk, S., Lanzloth, C., Brackrock, V., López-López, T., Graute, S., Aranda-Pardos, I., Hamley, M., Bahn, J., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20242079
“…of toxic bile acids within parenchymal cells has been described as a trigger of increased hepatocytes and cholangiocytes sensitivity to DR5 and TRAIL-mediated signals, leading to their apoptosis and significantly contributing to cholestatic liver injury (Higuchi et al., 2002; Takeda et al., 2008).”
ANCHR regulates TRAIL-mediated apoptosis with implications for liver injury
Gabrielyan, A., Simpson, D. S., Bandala‐Sanchez, E., Tenev, T., Lechtenberg, B. C., Saggau, J., Bonasera, D., Glatter, T., Orme, M. H., Kueh, A. J., et al. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45090
Raffi, G. C., Chen, J., Passchier, E. M., Lieftink, C., Papagianni, C., Leusen, J. H. W., Beijersbergen, R. L., Wang, L., & Bernards, R. (2026) · FEBS Journal · doi:10.1111/febs.70669
Orchestrated cell death pathways in cholangiopathies
Guicciardi, M. E., Pistorio, V., Soret, P., Steunou, V., Gores, G. J., & Gautheron, J. (2026) · Gut · doi:10.1136/gutjnl-2026-339264
Metadata
- Authors
- Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., Cretney, E., Yagita, H., Sueyoshi, N., Sato, N., Nakanuma, Y., Smyth, M. J., & Okumura, K.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Trung tâm Nghiên cứu Y sinh (VN)
- Juntendo University (JP)
- Kanazawa University (JP)
- University of Bern (CH)
- *Department of Immunology,
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-08-05
- Volume
- 105
- Issue
- 31
- Pages
- 10895-10900
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2504811
- OpenAlex
- W2171653534
- Semantic Scholar
- 808def9695bd321dc3e05100e71a911d21259847
- Cited by
- 148
- References
- 45
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 5 · 2023: 12 · 2022: 3 · 2021: 5 · 2020: 6 · 2019: 11 · 2018: 3 · 2017: 13 · 2016: 2 · 2015: 6 · 2014: 10 · 2013: 14 · 2012: 11
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- DR5, TRAIL receptor 2, apoptosis, cholestatic liver disease, primary sclerosing cholangitis, primary biliary cirrhosis, cholangiocytes, cholangitis, common bile duct ligation, liver fibrosis, TRAIL
- MeSH terms
- Animals, Antibodies, Monoclonal, Cholangitis, Cholestasis, Flow Cytometry, Humans, Immunohistochemistry, Mice, Mutant Strains, Apoptosis, Cell Line, Tumor, Mice, Receptors, TNF-Related Apoptosis-Inducing Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.